retatrutide triple agonist glp-1 gip glucagon phase 3 2025 Dual and Gut Peptide Agonists on the Horizon for the Treatment of Type 2 Diabetes and Obesity. An Overview of Preclinical and Clinical Data | Current Obesity Reports Synedica Retatrutide | Triple Agonist
Description
Patients on GLP-1 medications should hold daily doses on the day of the procedure and weekly doses seven days prior to surgery
22 One patient had severe acute pancreatitis, and there was one pancreatitis-related death
Liquid biopsy approach to pancreatic cancer
The systems that matter most for dementia prevention In longevity medicine, the practical question is not whether one therapy is good for the brain. The better question is whether the persons overall biology is moving toward resilience or vulnerability
Statins and the risk of acute pancreatitis: a population-based case-control study
In addition, BCBSM will change prior authorization requirements in this space on Saxenda, Wegovy and Zepbound beginning Aug
